<DOC>
	<DOCNO>NCT00362180</DOCNO>
	<brief_summary>This study ass , , effect ISIS 301012 ( mipomersen ) liver triglyceride content multiple group subject vary degree risk hepatic steatosis . In order enroll subject group vary degree risk , study include multiple cohort ( Cohorts A-G ) . Additions removal cohort accomplish protocol amendment .</brief_summary>
	<brief_title>Measure Liver Fat Content After ISIS 301012 ( Mipomersen ) Administration</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled study measure effect treatment mipomersen liver triglyceride ( TG ) content patient vary degree hyperlipidemia risk hepatic steatosis . The original study design include 4 cohort ( Cohorts A D ) . Subsequent protocol amendment add 3 cohort ( Cohorts E , F , G ) study , truncate enrollment Cohort D , eliminate Cohorts B C. The study consist 3-week screening period ; 4-week ( Cohorts A D ) , 13-week ( Cohort E ) , 52-week ( Cohort G ) treatment period ; 20-week post-treatment follow-up period . Cohort F observational cohort , therefore , treat study drug . Patients cohort underwent 15-week Magnetic resonance spectroscopy ( MRS ) ultrasound evaluation period . The study cohort : Cohort A : Healthy volunteer LDL-C &lt; 140 mg/dL ( 3.6 mmol/L ) , serum TG &lt; 200 mg/dL ( 2.3 mmol/L ) , hemoglobin A1c ( HbA1c ) &lt; 6.0 % , hepatic TG content &lt; 5 % ( measure MRS screen ) . Patients randomize mipomersen 200 mg placebo treat 4 week . Cohorts B+C eliminate protocol amendment prior enrol patient discuss . Cohort D : In amendment protocol , Cohort D close enrollment . One patient already enrol study prior amendment . The patient enrol cohort impair fast glucose ( define fast blood glucose &gt; 6 mmol/L &lt; 7 mmol/L ) mixed dyslipidemia ( LDL-C &lt; 215 mg/dL [ 5.6 mmol/L ] serum TG &gt; 200 mg/dL [ 2.3 mmol/L ] ) . The patient treat mipomersen 200 mg 4 week . Cohort E : Patients uncomplicated heterozygous familial hypercholesterolemia ( HeFH ) ( Alanine aminotransferase ( ALT ) ≤1.5 * upper limit normal Upper limit normal ( ULN ) , evidence insulin resistance metabolic syndrome , hepatic TG content &lt; 5 % MRS screening ) . Patients remain baseline statin ± ezetimibe regimen wash lipid-lowering agent ( e.g. , fenofibrate , non-dietary omega-3 fatty acid , niacin ) least 8 week prior MRS screen . Patients randomize either mipomersen 200 mg placebo 13 week . Cohort F : Patients familial hypobetalipoproteinemia ( FHBL ) ( document APOB gene mutation result expression truncate form apo B ) . Patients cohort evaluate MRS , ultrasound , laboratory test ; however , treat mipomersen placebo . Cohort G : Patients well-controlled type 2 diabetes mellitus ( HbA1c ≤8.0 % ) , hypercholesterolemia ( LDL-C &gt; 100 mg/dL ( 2.59 mmol/L ) , normal serum TG level ( ≤200 mg/dL [ 2.26 mmol/L ] ) . Patients stable dose antidiabetic lipid-lowering medication &gt; 3 month prior screen expect remain stable duration study . Patients randomize either mipomersen 200 mg placebo 26 week , follow 26 additional week mipomersen 200 mg . Recruiting difficulty cause cohort close early .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Lipid Metabolism Disorders</mesh_term>
	<mesh_term>Infant , Newborn , Diseases</mesh_term>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Genetic Diseases , Inborn</mesh_term>
	<mesh_term>Lipid Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Hypobetalipoproteinemias</mesh_term>
	<mesh_term>Hypolipoproteinemias</mesh_term>
	<mesh_term>Mipomersen</mesh_term>
	<criteria>Group A healthy subject Group D impair fast glucose mixed dyslipidemia Group E diagnosis Heterozygous Familial Hypercholesterolemia ( HeFH ) stable lipidlowering therapy 3 month Group F diagnosis Familial Hypobetalipoproteinemia ( FHBL ) Group G diagnosis Diabetes hypercholesterolemia Medical , surgical , laboratory condition judgment Physician Investigator would make subject unsuitable enrollment , potentially interfere subject participation completion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>LDL-cholesterol</keyword>
	<keyword>apoB-100</keyword>
	<keyword>apoB-48</keyword>
	<keyword>triglyceride</keyword>
	<keyword>HeFH</keyword>
	<keyword>FHBL</keyword>
</DOC>